PHARMACOKINETICS AND METABOLISM OF THE FLAVONOID SCUTELLARIN IN HUMANS AFTER A SINGLE ORAL ADMINISTRATION

Xiaoyan Chen, Liang Cui, Xiaotao Duan, Bin Ma, and Dafang Zhong

Center for Drug Metabolism and Pharmacokinetics Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China (X.C., D.Z.); and Laboratory of Drug Metabolism and Pharmacokinetics, Shenyang Pharmaceutical University, Shenyang, P.R. China (L.C., X.D., B.M.)

Received February 10, 2006; accepted May 16, 2006

ABSTRACT:

Scutellarin is widely used in treating various cardiovascular diseases. Few data are available regarding its metabolism and pharmacokinetics in humans. The objectives of this study were to develop methods to identify major metabolites of scutellarin in human urine and plasma and to determine simultaneously the parent drug and its major metabolites in human plasma for pharmacokinetic studies. Four metabolites were detected in urine samples by liquid chromatography coupled with electrospray multi-stage mass spectrometry (MS), but only one of them was found in plasma. Its structure was confirmed as scutellarein 6-O-β-D-glucuronide by MS, NMR, and UV absorbance spectra. The plasma concentrations of scutellarin and the major metabolite were simultaneously determined using liquid chromatography-tandem MS. After a single p.o. administration of 60 mg of scutellarin to 20 healthy subjects, the plasma concentrations of scutellarin were very low, and its plasma concentration-time curve was also anomalous. Plasma concentration of the major metabolite was comparatively high, and the peak plasma concentration was 87.0 ± 29.1 ng/ml. The T_max was late (7.85 ± 1.62 h), and part of individual pharmacokinetic profiles showed double peaks, which indicated scutellarin could be absorbed into the intestine after hydrolysis to its aglycone by bacterial enzymes. This was followed by reconjugation in the intestinal cell and/or liver with glucuronic acid catalyzed by the phase II enzyme, which showed regioselectivity and species difference. The regioselectivity of glucuronooconjugation for scutellarin may be of importance for pharmacological activity. Plasma concentration of isoscutellarin can be used as a biomarker of scutellarin intake.

Flavonoids are among the most ubiquitous groups of plant secondary metabolites distributed in various foods and medicinal plants. They have a variety of biological effects in numerous mammalian systems in vitro and in vivo: free radical scavenger, antioxidant, anti-inflammatory, antimutagen, or purgative effects. Recently, an increasing number of publications on the beneficial health effects of flavonoids, such as in cancer, coronary heart, and stroke diseases, have appeared (Le Marchand, 2002; Nestel, 2003). These effects could be explained by their abilities to inhibit the cell cycles, cell proliferation, or oxidative stress, improve the efficacy of detoxification enzymes, induce apoptosis, and stimulate the immune system.

Scutellarin (Fig. 1), scutellarein 7-O-β-D-glucuronide, is one of the major bioactive flavonoid glucuronides isolated from a Chinese herb, *Erigeron brevisscapus* (Vant). This compound is also found in *Teucrium parvifolium*, *Tripora divaricata* (Grayer et al., 2002), and *Scutellaria lateriflora* (Gafner et al., 2003). It has been reported that scutellarin was useful in the therapy of various ailments, such as cardiovascular diseases, sleep disorders, depression, migraine, pain, and memory impairment (Pouzet, 2002; Gafner et al., 2003; Goh et al., 2005). Today, it is commonly used in China as a remedy in dilating blood vessels, improving microcirculation, decreasing the viscosity of blood, reducing the blood platelet count, and inhibiting platelet aggregation activity (Hong and Liu, 2004; Liu et al., 2005).

With the increasing significance of a potential beneficial role of scutellarin in human health, there is a growing demand for research on its absorption, metabolism, and excretion. Until now, reports on pharmacokinetics and metabolism of scutellarin only focused on animals (Jiang et al., 2003; Liu et al., 2003; Zhang et al., 2003; Huang et al., 2005). Shen and Feng (2006) reported a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to directly determine scutellarin in human plasma and described its pharmacokinetic curve with the mean C_max value of c.a. 12.0 ng/ml after a p.o. dose of 60 mg of scutellarin. A similar method was developed in our laboratory, but we found that the plasma concentrations of scutellarin in humans after a p.o. administration were very low, and its plasma concentration-time curve was anomalous, which implied that scutellarin might undergo extensive first-pass metabolism in humans. As a result, determination of parent drug in plasma may not reflect its pharmacokinetic process in humans. Therefore, it is necessary to identify the major metabolites of scutellarin in human plasma and further investigate its pharmacokinetics.

Over the past 2 decades, liquid chromatography coupled with mass spectrometry (LC/MS) has proved to be one of the most effective

ABBREVIATIONS: LC/MS/MS, liquid chromatography/tandem mass spectrometry; LC/MS, liquid chromatography/mass spectrometry; LC/MSn, liquid chromatography/ion trap mass spectrometry; HPLC, high-performance liquid chromatography; ESI, electrospray ionization; QC, quality control; AUC, area under the plasma concentration-time curve.
Scutellarin (96.5% purity) and baicalin (internal standard, 98.0% purity) were supplied by Liaoning Institute for the Control of Pharmaceutical Products (Shenyang, China). Isoscutellarin (94.1% purity by high-performance liquid chromatography (HPLC)), a major metabolite of scutellarin, was isolated and prepared from human urine in our laboratory.

In the present study, we first identified scutellarin metabolites in humans with liquid chromatography/ion trap mass spectrometry (LC/MS²). On this basis, we developed a rapid, selective, and sufficiently sensitive LC/MS/MS method to simultaneously determine scutellarin and its major metabolite in human plasma and to characterize the absorption and the plasma pharmacokinetics after a p.o. administration of 60 mg of scutellarin.

Materials and Methods

Chemicals. Scutellarin (96.5% purity) and baicalin (internal standard, 98.0% purity) were supplied by Liaoning Institute for the Control of Pharmaceutical Products (Shenyang, China). Isoscutellarin (94.1% purity by high-performance liquid chromatography (HPLC)), a major metabolite of scutellarin, was isolated and prepared from human urine in our laboratory.

Subjects. Twenty healthy male Chinese volunteers participated in the pharmacokinetic study after giving written informed consent. Their ages ranged from 20 to 28 years (mean, 23 years) and their weights from 58 to 75 kg (mean, 64 kg). The subjects were all apparently healthy with no history of disease of the gastrointestinal tract, such as lactose intolerance or irritable bowel syndrome. They had neither suffered from any illness nor taken any other medicines in the preceding 2 weeks. The study was approved by the Ethical Committee of the People’s Hospital of Liaoning Province (Shenyang, China).

Study Design. Each subject swallowed a 60-mg dose of scutellarin dripping pills (Qiu et al., 2005) with 200 ml of water. Serial blood samples were collected into heparinized vacuum tubes before dosing and at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 13, 15, and 24 h after dosing, and were immediately centrifuged for 10 min at 2500g at 4°C to separate the plasma fractions. The obtained plasma samples (1.5 ml) were immediately transferred into a plastic tube containing 100 μl of 8 M phosphoric acid and then vortex-mixed. The acidified plasma samples were stored frozen at –20°C until analysis. The volunteers voided immediately before the dose was administered, and urine was collected from 8 to 12 h over wet ice into tubes. The collected urine samples were acidified by 8 M phosphoric acid and then were stored frozen at –20°C until analysis.

LC/MS² Procedures for Metabolites Analysis. A Finnigan LCQ ion trap mass spectrometer (San Jose, CA) equipped with an electrospray ionization (ESI) source system and an Agilent 1100 HPLC system (Wilmington, DE) consisting of a vacuum degasser, a binary pump, and an autosampler were used to identify the metabolites of scutellarin in human urine or plasma samples. The LCQ interface was adjusted to the following conditions: ion mode, positive; spray voltage, 4.5 kV; capillary temperature, 220°C; sheath gas (nitrogen), 50 Ar; and auxiliary gas (nitrogen), 5 Ar. The full-scan mass spectrum to obtain the protonated molecules [M + H]⁺ of each potential metabolite was collected in the mass range from m/z 150 to 900. Furthermore, MS/MS and MS² spectra were obtained for selected precursor ions through incidental collision with neutral gas (helium) molecules in the ion trap, which could provide characteristic fragment ions of each metabolite. The relative collision energy was set at 30 to 40%.

To simultaneously detect phase I and phase II metabolites, a gradient of two solvent systems, A and B, was used. Solvent A was water containing 0.1% formic acid; solvent B was methanol containing 0.1% formic acid. The gradient started at 50% A/50% B for 13 min, followed by a linear increase of solvent B to 80% in 1 min. This rate composition was maintained from 14 min to 30 min, and the initial conditions were returned to in 1 min, followed by a stable phase of 5 min. The flow rate was delivered at a constant flow rate of 0.5 ml/min. Chromatographic separation was achieved using a 200 × 4.6-mm, 5-μm Diamonsil C₁₈ column (Dikma, Beijing, China) with a 4 × 3.0-mm SecurityGuard C₁₈ (5-μm) guard column (Phenomenex, Torrance, CA). The column temperature was maintained at 25°C.

A simple solid-phase extraction procedure was used to extract scutellarin and its metabolite from urine or plasma samples. Aliquots (1.0 ml) of urine or plasma samples collected from volunteers were applied to Supelclean LC-18 solid-phase extraction column (2 ml, Supelco, Bellefonte, PA) preconditioned with 2-ml aliquots of methanol and water. After loading the sample, the column was washed with 1 ml of water. Metabolites were eluted with 1 ml of methanol containing 0.5% formic acid. The eluate was evaporated to dryness at 40°C under a gentle stream of nitrogen, and the residue was reconstituted by addition of 200 μl of the initial mobile phase. A 20-μl aliquot of the solution was injected onto the LC/MS² system.

Preparation and Identification of Metabolites. A semipreparative HPLC system was used to purify metabolites, consisting of two LC-6AD solvent delivery units, a DGU-14A degasser unit, an SPD-10A VP UV-visible detector, and an FRC-10A fraction collector. A Bruker AMX 300 NMR spectrometer (Faellanden, Switzerland) was used to record 1H NMR (300 MHz) and 13C NMR (75 MHz) spectra. Resonances are reported relative to dimethyl sulfoxide at 2.50 ppm.

Quantification of Scutellarin and Its Major Metabolite in Human Plasma. Scutellarin and its major metabolite (isoscutellarin) were simultaneously determined in human plasma using a sensitive and selective LC/MS/MS method. Briefly, to a 500-μl aliquot of acidified plasma, 100 μl of the internal standard (400 ng/ml baicalin) and 200 ng/ml of water were added. This mixture was extracted with 3 ml of ethyl acetate. The organic phase was separated, evaporated to dryness, reconstituted, and injected into the LC/MS/MS system, which consisted of a Shimadzu (Kyoto, Japan) LC-10AD solvent delivery pump, an SIL-HT, autosampler, and a Thermo Finnigan TSQ Quantum Ultra triple-quadrupole mass spectrometer fitted with an Ion Max ESI interface. The mass spectrometer was operated in the positive ion detection mode. Selected reaction monitoring included m/z 463→m/z 287 for scutellarin and the metabolite m/z 447→m/z 271 for baicalin, respectively, with a dwell time of 0.20 s per transition. The same column described above was used for isocratic chromatographic separation. The mobile phase was composed of methanol and water (65:35, v/v) with 0.1% formic acid at a flow rate of 0.6 ml/min.

For preparation of standard curves, the stock standard solutions of scutellarin and the metabolite, isoscutellarin, were prepared by dissolving the accurately weighed standard compounds in methanol to give final concentrations of 400 μg/ml for each analyte. The solutions were then successively diluted with a mixture of methanol/water/formic acid (50:50:0.5, v/v/v) to achieve standard working solutions at concentrations of 500, 250, 100, 40.0, 15.0, 5.0, and 2.0 ng/ml for scutellarin and 4000, 2000, 1000, 300, 100, 40, 15.0, and 5.0 ng/ml.
for isoscutellarin. The obtained standard working solutions of scutellarin and isoscutellarin (50 μl each) were used to spike acidified blank plasma samples (0.5 ml) and vortex-mixed. The mixed plasma samples were treated as described above, both in pre-study validation and during the pharmacokinetic study for the preparations of standard curves. The final standard concentrations in human plasma were 0.20 to 50.0 ng/ml for scutellarin and 0.50 to 400 ng/ml for isoscutellarin. The quality control (QC) samples were prepared using different stock solutions to obtain the plasma concentrations of 0.50, 5.0, and 45.0 ng/ml for scutellarin and 1.0, 20.0, and 360 ng/ml for isoscutellarin, representing low, medium, and high concentration of QC samples, respectively.

During pre-study validation, the calibration curves were defined in 3 days based on triplicate assays of the spiked plasma samples, and QC samples were determined in replicates (n = 6) on the same day. Peak area ratios of each analyte to the internal standard were used for the construction of calibration curves, using 1/x² weighted linear least-squares regression of plasma concentrations. Excellent linearity was obtained over the concentration range of 0.20 to 50.0 ng/ml for scutellarin and 0.50 to 400 ng/ml for isoscutellarin in human plasma. Typical equations of calibration curves were as follows: scutellarin: \( y = (3.236 \pm 0.316) \times 10^{-5} x + (4.093 \pm 1.185) \times 10^{-4}, r = 0.9970 \pm 0.0012; \) isoscutellarin: \( y = (2.596 \pm 0.258) \times 10^{-5} x + (3.545 \pm 0.225) \times 10^{-4}, r = 0.9987 \pm 0.0001. \)

The lower limits of quantification for determination of scutellarin and isoscutellarin in plasma, defined as the lowest concentrations analyzed with accuracy within ±15% and a precision ±15%, were 0.20 and 0.50 ng/ml, respectively. The intraday and interday relative S.D., calculated from QC samples, were <10.2% for scutellarin and <5.3% for isoscutellarin. The interday relative error as determined from QC samples was within ±2.3% for each analyte. Extraction recoveries for scutellarin at concentrations of 0.50, 5.0, and 45 ng/ml were 52.4 ± 4.6, 48.2 ± 3.7, and 48.7 ± 2.1% (n = 6), respectively; the recoveries for the metabolite at 1.0, 20.0, and 360 ng/ml levels were 45.6 ± 2.8, 45.3 ± 4.6, and 47.2 ± 3.4% (n = 6), respectively. The results of stability experiments showed that no significant degradation occurred during chromatography, extraction, and three-freeze-thaw cycles and sample storage processes (~20°C for 60 days) for scutellarin and the metabolite in acidified plasma samples (deviating no >10% at low, high nominal concentrations for each analyte). The analytical data showed excellent reproducibility, specificity, sensitivity, and precision for measurement of scutellarin and its metabolite.

The above-validated method was applied to the pharmacokinetic study of scutellarin and its metabolite after a p.o. dose of 60 mg of scutellarin to 20 healthy volunteers. During the routine analysis, one set of calibration standards and two sets of QC samples were extracted and assayed along with the unknown samples. The plasma concentrations of unknown samples and QC samples were calculated according to the standard curve within each run. Pharmacokinetic Analysis. The main pharmacokinetic parameters were calculated by model-independent methods. The peak plasma concentration (Cmax) and the time to reach it (Tmax) were taken directly from the data. The elimination half-life (t1/2) was calculated from the equation t1/2 = ln2/k, using the terminal monoexponential log-linear slope of the time versus concentration curve of each subject for the estimation of k by least-squares regression. The area under the plasma concentration-time curve (AUC(0→∞)) was calculated by the linear trapezoidal method. The total body clearance (CL/F) and steady-state volume of distribution (Vss/F) were calculated as follows: CL/F = dose/AUC and Vss/F = mean residence time × CL/F. All the data are expressed as mean ± S.D.

Results

Identification of Scutellarin Metabolites. The metabolism of scutellarin has been investigated in rats. Four metabolites were identified, including two sulfate conjugates of scutellarin, 6-methyl-scute- llarin and 6-methyl-scullarein (6-methyl of aglycone) (Zhang et al., 2003). However, studies on the metabolism of scutellarin in humans have not been reported until now. In this experiment, an ion trap mass spectrometer was used to identify the major metabolites of scutellarin in humans because it does not suffer the sensitivity losses during the full-scan mode that are unavoidable to a triple-quadrupole mass spectrometer. Scutellarin is a flavone 7-O-glucuronide, and its mass spectrometer signal intensity obtained in the positive mode was higher than that in the negative mode. In addition, ESI source revealed much higher signals for the protonated molecule of scutellarin at m/z 463 compared with atmospheric pressure chemical ionization source.

To profile for potential metabolites of scutellarin, the urine or plasma samples were first analyzed by the LC/MS² method via full-scan mode in the mass range from m/z 150 to 900. No appreciable metabolite peaks were observed in the total ion current chromatogram. Therefore, possible metabolites of scutellarin were screened from total ion current chromatogram by selected ion monitoring mode, including conjugates of scutellarin with one or two sulfate groups (m/z 543 or 623), with glucuronic acid (m/z 639 or 815), with glucose (m/z 625 or 787) or methylated metabolites (m/z 477 or 491), and aglycone (scutellarein, m/z 287), as well as methylated aglycone (m/z 301) or aglycone conjugates with sulfuric acid or glucuronic acid (m/z 367 or 463). The selected ion monitoring chromatogram by monitoring the [M + H]⁺ ion at m/z 463 showed six peaks (Fig. 2B). But by comparison of blank urine, only three peaks with the retention times of 7.31, 9.03, and 9.83 min, respectively, were identified as the metabolites of scutellarin in humans and designated as M-1, M-2 (major peak), and M-3 (minor peak), respectively. Compared with blank urine, another metabolite showing [M + H]⁺ ion at m/z 477 was observed, and named as M-4 (tR = 27.05 min) (Fig. 2B). To further investigate the structures of the four metabolites, full-scan MS/MS and MS³ modes (Fig. 3) were applied to obtain the characteristic fragments ions. The MS/MS spectra of M-1, M-2, and M-3 all yielded relatively a simple fragment ion at m/z 287 derived from the neutral loss of glucuronic acid moiety (~176 Da), which was identical to the MS/MS spectrum of scutellarin. M-1 also had the same HPLC retention time (7.31 min) with the parent drug. Based on these data, M-1 was identified as scutellarin and M-2 and M-3 as its isomeric forms that arose from variation in the positioning of the glucuronyl moiety on the flavonoid ring. Scutellarin has three potential sites for glucuronidation at 5-, 6-, and 4'-OH groups, respectively. The exact position of the glucuronosyl moiety could not be identified at this stage.

The MS/MS spectrum of M-4 gave an abundant peak at m/z 301 because of loss of glucuronic acid. Its [M + H]⁺ ion, 14 Da higher than that of the parent drug, suggested that M-4 could be a methylated scutellarin. Furthermore, full-scan MS³ spectrum of m/z 477→301 yielded a major fragment ion at m/z 286 (Fig. 3), which is the characteristic fragment ion of methylated flavonoids. The potential sites of methylation for M-4 could not be elucidated only based on MS³ data.

Four metabolites could be detected in urine samples of all the subjects. However, only M-2 and trace amount of parent drug were found in plasma samples. Time course analysis of scutellarin and its metabolites showed that the predominant metabolite in plasma and urine was M-2. To investigate scutellarin pharmacokinetics in humans, it is necessary to further identify the structure of M-2 and obtain its plasma concentration-time curves.

The collected urine samples were initially acidified to pH 2 to 3 by 8 M phosphoric acid and further extracted using ethyl acetate. The extract was removed under reduced pressure. The obtained residue was dissolved in methanol and subjected to XAD-2 chromatography using a gradient of H₂O and methanol system to obtain M-1-containing fractions. These fractions were subjected repeatedly to silica gel chromatography using methanol-H₂O (1:1) and finally were purified by semipreparative HPLC on a Shim-pack PRP-ODS column (250 × 20 mm i.d., Shimadzu, Kyoto, Japan) using a gradient of methanol and H₂O (1:4–7:3) to give the compound M-2 (c.a., 70 mg). Its structure was characterized by MS and NMR spectra. The
positive ESI/MS spectrum showed that the purified compound corresponds to the monoglucuronide derivative and has the same molecular weight as that of the parent drug. The $^{13}$C NMR spectrum of M-2 showed six carbon signals assigned to be a glucuronic acid moiety, including one anomeric carbon (104.3 ppm) and one carboxyl carbon (170.9 ppm), besides those of an aglycone moiety (Table 1). In the $^1$H NMR spectrum, a sequential trans-1,2-diaxial relationship of H-1'-H-5' (4.87–3.60 ppm, $J = 6.3–9.2$ Hz) indicated the presence of a $\beta$-d-glucuronylpyranosyl moiety in M-2. The complete identification of the structure of M-2, especially located position for glucuronyl group, was established by $^1$H- and $^{13}$C-NMR and UV absorption analysis. Table 1 presents the $^{13}$C and $^1$H NMR chemical shift values and $^1$H NMR coupling constants from the parent drug and the major metabolite M-2. Comparison of the chemical shift values of the
aromatic protons of M-2 with the $^1$H NMR spectrum of scutellarin reveals that only the C8-H, represented by a singlet at 7.04 ppm shifts by -0.5 ppm toward 6.54 ppm. The $^1$H NMR signals of C2-H, C3-H, C5-H, C6-H, and C3-H are almost similar to those of the parent drug, which indicated that the glucuronic acid moiety of M-2 was conjugated with hydroxyl group in A ring. Therefore, this metabolite can be either the 5-O- or 6-O-glucuronosyl of scutellarein. In addition, similar to that of the parent drug, $^1$H NMR spectrum of this metabolite shows a broad singlet signal at 12.77 ppm, which derived from a resonance of the 5-OH group of the flavonoids (Abe et al., 1990), because of lack of rapid exchange with solvent resulting from strong hydrogen bonding of the OH-hydrogen to the 4-keto moiety. As a result, the metabolite M-2 cannot be the 5-O-glucuronosyl of scutellarein and was confirmed as scutellarein 6-glucuronide, named isoscutellarin. The shift difference in the ppm value of C5-OH (-0.46 ppm) was observed between $^1$H NMR spectra of scutellarin and M-2 caused by the glucuronosyl moiety attached at C6-OH. In addition, in $^{13}$C NMR spectrum of M-2, the different shifts of C-5, C-6, and C-7 can be explained by the glycosidation shift rule of phenolic hydroxyl group, which leads to the upfield shift (-2.1 ppm) of the ipso-carbon signal (C-6) and the downfield shift (+6.2, +7.2) of the ortho-carbon signals (C-5, C-7). The structural elucidation of the metabolite was further supported by UV absorption spectroscopy. When 5 μM AlCl₃ was added to methanol solution of M-2, the absorbance peaks of M-2 at 323 and 283 nm increased and shifted to 338 and 293 nm, respectively. Furthermore, followed by 1 M HCl, the UV peak did not shift. These results indicated that M-2 did not contain ortho-dihydroxyl substitutions but has a free 5-OH group.

![Fig. 3. Full-scan MS² spectra corresponding to the metabolite peaks. A, MS/MS spectrum of the peak eluting at 7.31 min. B, MS/MS spectrum of the peak eluting at 27.05 min. C, MS³ spectrum of the peak eluting at 27.05 min.](image-url)
The reference substance of the metabolite M-3 was not obtained in this experiment because its amount in urine samples from the volunteers was very low. Because the LC/MS data indicated it to be a positional isomer of scutellarin, and the 6- and 7-monoglucuronosyls were already identified, the one residual monoglucuronosyl for M-3 only can be the 5-O- or 4′-O-glucuronosyl of scutellarin, which both contained an ortho-dihydroxyl substitution. Therefore, the UV absorption spectrum was not suitable to elucidate the glucuronosyl position of M-3. Because of the strong hydrogen bonding of the 5-OH-5-H11032/4- hydroxyl group in the B-ring of flavonoids decreased the antioxidant activity to a lesser extent (Brown et al., 1998).

**Discussion**

Flavonoids are polyphenol compounds. Their pharmacological effects have been reported to be highly dependent on the number and position of the hydroxyl moieties in the molecule (Bors et al., 1990; Rice-Evans et al., 1996). The hydroxyl groups in the structure are mainly metabolized as conjugates with a glucuronic acid or sulfuric acid during the phase II biotransformation pathway in vertebrates (Morand et al., 1998; Havsteen, 2002). Therefore, the difference in conjugated positions can be expected to influence their biological activities. It has been reported that glucuronidation of the 3′- or 4′-hydroxyl group in the B-ring of flavonoids decreased the antioxidant activity, whereas glucuronidation in the A-ring affected antioxidant activity to a lesser extent (Brown et al., 1998).

It has been shown that the preferential conjugation sites exist in the conjugate formation for flavonoid compounds, which may be related to the steric configuration of the flavonoids or the UDP-glucuronosyltransferase involved (species difference) (Boersma et al., 2002; O'Leary et al., 2003; Yodogawa et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et al., 2003; Gradolatto et al., 2004; Chen et
al., 2005). For some flavonoids, such as naringin or naringenin (Zhang et al., 2005), the major metabolites in rat urine were 4′-O-glucuronide, followed by 7-O-glucuronide. Because of the low acidity, the 5-OH position was well known to be the least reactive for glucuronidation. Only one literature reported that a minor 5-OH-glucuronide was observed in vivo when rats were fed an isoflavone-rich diet (Fang et al., 2002). Until now, few data about the 6-OH metabolic reactivity were available. A 6-O-glucuronosyl type metabolite was identified when investigating the metabolism of baicalein and baicalin (baicalein 7-O-glucuronide) in human or rat urine (Abe et al., 1990; Che et al., 2001). But no quantitative comparison of the glucuronidation capacity for 6-OH and 7-OH groups has been made in the literature. In our study, three monoglucuronide isomers of the aglycone substituted on 6-, 4′-, or 7-OH were observed in human urine after a p.o. administration of scutellarin. Among them, the major metabolite was scutellarin-6-O-glucuronide, followed by scutellarin-4′-O-glucuronide, and 7-O-glucuronide (the parent drug) as a minor metabolite, implying that the 6-OH group of scutellarin (or scutellarin) was the preferential site for glucuronosyl conjugation in humans. Similar sites for monoglucuronidation of scutellarin were observed in rat urine, but the ratio of the formed products was different from that of the present study. The parent drug (scutellarin-7-O-glucuronide) was a major monoglucuronon conjugate, and only a small amount of 6-O-glucuronide was detected in rat urine. Until now, no scutellarin-6-O-glucuronide was found in the plant kingdom. These results illustrate that the regioselectivity of glucuronosyl conjugation to scutellarin is species-different (variable UDP-glucuronosyltransferase selectivity). To the flavonoids containing the 6-OH group, the 6-O-glucuronide conjugation may be an important metabolic pathway in humans. The effect of conjugation on biological activities remains to be investigated.

No sulfoconjugates were detected in this experiment by LC/MS® and specific enzymatic hydrolysis (β-glucuronidase-sulfatase/b-saccharic acid 1,4-lactone) methods (Yodogawa et al., 2003), probably because of the inhibitory effect of scutellarein on phenol sulfotransferase (Walle et al., 1995).

There has been some controversy regarding how flavonoids are absorbed, and it has been suggested that some flavonoids, mainly those with glucose molecules, might be absorbed intact (Hollman et al., 1999). However, flavonoids such as rutin, hesperidin, naringin, narinrutin, and baicalin, which contain sugar (rutinoses, neoheesperidoses, or glucuronic acid) chains, are most likely hydrolyzed to their aglycones by intestinal enzymes of bacterial origin, such as α-rhamnosidases and β-glucuronidase (Choudhury et al., 1999; Hollman et al., 1999; Akao et al., 2000; Erlund et al., 2000; Spencer, 2003; Walle, 2004), and are then absorbed into the intestinal cells by passive mechanisms. The absorbed aglycone may be efficiently conjugated as glucuronides, sulfates, or methylated derivatives; however, it is not clear where the conjugation of the aglycone occurred, especially glucuronidation, because both human intestinal and liver tissue have been shown to possess UDP-glucuronosyltransferase activity. It has been reported that glucuronidation process for catechin, resveratrol, queretin, and luteolin occurred mainly in the small intestine (Kuhnle et al., 2000; Donovan et al., 2001; Spencer, 2003). In our study, after a p.o. administration of scutellarin, the major component in plasma is its isomer, and the parent drug was hardly detectable. The peak plasma concentrations of the major metabolite were reached between 5.0 and 11 h (mean, 7.85 h), and part of individual profiles (~30%) showed double peaks. These results indicated that scutellarin was hydrolyzed to the corresponding aglycone, which was absorbed from the small intestine or the colon, followed by a regioselective glucuronidation to form scutellarin-6-O-glucuronide to enter the blood.

![FIG. 4. Plasma concentration-time profiles of scutellarin and its major metabolite after a p.o. dose of 60 mg of scutellarin. A, typical individual plasma concentration-time profile of the parent drug. B, mean plasma concentration-time profile of isoscutellarin (n = 20). Each point represents the mean ± S.D.](image)

### TABLE 2

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Mean (ng/ml × h)</th>
<th>S.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC&lt;sub&gt;n&lt;/sub&gt;</td>
<td>459.3</td>
<td>151.4</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;n-&lt;/sub&gt;</td>
<td>464.0</td>
<td>154.0</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt; (h)</td>
<td>3.08</td>
<td>0.55</td>
</tr>
<tr>
<td>AUMC&lt;sub&gt;n&lt;/sub&gt; (ng/ml × h&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>4017</td>
<td>2029</td>
</tr>
<tr>
<td>AUMC&lt;sub&gt;n-&lt;/sub&gt; (ng/ml × h&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>4102</td>
<td>2090</td>
</tr>
<tr>
<td>MRT (h)</td>
<td>8.87</td>
<td>2.10</td>
</tr>
<tr>
<td>CL/F (l/h)</td>
<td>147.9</td>
<td>75.8</td>
</tr>
<tr>
<td>V/D/F (liters)</td>
<td>690.1</td>
<td>400.7</td>
</tr>
<tr>
<td>V/D&lt;sub&gt;F&lt;/sub&gt; (liters)</td>
<td>1206</td>
<td>481.9</td>
</tr>
<tr>
<td>Tmax (h)</td>
<td>7.85</td>
<td>1.62</td>
</tr>
<tr>
<td>Cmax (ng/ml)</td>
<td>87.01</td>
<td>29.14</td>
</tr>
</tbody>
</table>

The main pharmacokinetic parameters of isoscutellarin after p.o. administration of 60 mg of scutellarin to 20 healthy Chinese subjects.
stream. From our data, we cannot determine whether the isoscullerin is formed in the intestine and/or liver.

It was reported that human liver cells possessed β-glucuronidase and UDP-glucuronosyltransferase activity, which could further deglucuronidate some glucuronides and then reglucuronidate in liver (O’Leary et al., 2003). Therefore, it was inferred that the major metabolite isoscullerin could be hydrolyzed to the aglycone by β-glucuronidase in liver and then rejugucronidated with glucuronic acid to give scuttellarein-4′-O-glucuronide and scuttellarein-7-O-glucuronide (original form), which both were found in human urine. The reformation of the parent drug in liver may result in its anomalous plasma concentration-time curve (Fig. 4A).

The C_max and AUC values of isoscullerin exhibited wide interindividual variation. We hypothesize that these variations were caused by gastrointestinal microflora or their glucuronidation capacity. Large interindividual variation in bioavailability has also been reported to occur for quercetin-rutinoside (Erlund et al., 2000).

In summary, the use of LC/ESI/MS in multistage full-scan mode allowed us to identify the metabolites of scuttellarin in human urine and plasma samples. Two positional isomers were observed as its monoglucuronide metabolites in human urine, in which the isomer conjugated with the 6-OH group was the major metabolite in vivo and could be used as a biomarker of scuttellarin intake. Pharmacokinetic behavior of isoscullerin indicated that scuttellarin is most likely hydrolyzed by intestinal β-glucuronidase of bacterial origin, followed by a reconjugation step in the intestinal cell and/or in the liver with glucuronic acid after absorption of the aglycone, which showed the positional selectivity and species difference. In humans, the 6-OH group of the aglycone of scuttellarin was the preferential site for glucuronosyl conjugation compared with 4′-, 5-, and 7-OH groups.

Acknowledgments. We thank Dr. Rongqin Li at the People’s Hospital of Liaoning Province (Shenyang, China) for the conduct of the clinical study, and Dr. Jiang Zheng at the Northeastern University (Boston, MA) for helpful discussions.

References
Address correspondence to: Dafang Zhong, Center for Drug Metabolism and Pharmacokinetics Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 646 Songtiao Road, Shanghai 201203, P.R. China. E-mail: zhongdf@china.com